Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Veterans with MDD
NCT03053830Phase 2Completed
- Sponsor
- United States Department of Veterans Affairs
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by United States Department of Veterans Affairs. Primary endpoints: Montgomery-Asberg Depression Rating Scale, Quick Inventory of Depressive Symptomatology-Self Report and 9 more. Started Jan 2017; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03053830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053830.